Nasuh C Buyukkaramikli (Nasuh C Büyükkaramikli, Nasuh Büyükkaramikli)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 5

Top Venues

PharmacoEconomics

The European journal of health economics : HEPAC : health economics in prevention and care

Health technology assessment (Winchester, England)

Erasmus University Rotterdam

Bilkent Universitesi (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Erasmus University Rotterdam Jan 01 2014

Netherlands

Senior Researcher/Assistant Professor :: iMTA/ESHPM

Pharmerit Europe Jan 01 2011 - Jan 01 2014

Netherlands

Research Consultant

Education History

Bilkent Universitesi

Turkey

MSC :: Industrial Engineering

Publications

Nigel Armstrong, Nasuh C Buyukkaramikli, Hannah Penton, Rob Riemsma, Pim Wetzelaer, Vanesa Huertas Carrera, Stephanie Louise Swift, Thea Marie Drachen, Heike Raatz, Steve Ryder, Dhwani Shah, Titas Buksnys, Gill Worthy, Steven Duffy, Maiwenn Al, Jos M P Kleijnen
Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England) 24 (51) (2021)
Nasuh C Buyukkaramikli, Maureen P M H Rutten-van Mölken, Johan L Severens, Maiwenn Al
TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. PharmacoEconomics 37 (11) (2020)
Nasuh C Buyukkaramikli, Saskia de Groot, Rob Riemsma, Debra Fayter, Nigel Armstrong, Piet Portegijs, Steven Duffy, Jos Kleijnen, Maiwenn J Al
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 37 (2) (2020)
Nasuh C Buyukkaramikli, Peter Wigfield, Men Thi Hoang
A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England. The European journal of health economics : HEPAC : health economics in prevention and care 22 (1) (2020)
Nasuh C Buyukkaramikli, Saskia de Groot, Debra Fayter, Robert Wolff, Nigel Armstrong, Lisa Stirk, Gill Worthy, Fernando Albuquerque de Almeida, Jos Kleijnen, Maiwenn J Al
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. PharmacoEconomics 36 (2) (2019)

Nasuh C Buyukkaramikli.css-eqlu8i{font-size:small;padding-left:4px;} (Nasuh C Büyükkaramikli, Nasuh Büyükkaramikli)

Publication Activity (10 Years)

Top Topics

Top Venues

Nasuh C Buyukkaramikli (Nasuh C Büyükkaramikli, Nasuh Büyükkaramikli)